ABCL Abcellera Biologics Inc
Company Analysis
Latest News
🔴 Abcellera Biologics is trading 4.03% down today with no new reported catalyst
Abcellera Biologics is trading at $10.82 (-4.03%) with no new company announcement or clearly reported September 2 catalyst found. - Official releases show...
🔴 Abcellera Biologics is trading 4.6% down today
Abcellera Biologics is trading at $11.84, down 4.56%, with no newly reported company-specific catalyst identified for August 28, 2026. - Recent coverage...
🟢 Abcellera Biologics is trading 10.7% up today as biotech sector gains
Abcellera Biologics is trading at $11.74, gaining +10.70% amid biotech-sector strength and continued optimism following recent Moderna-Merck trial news. - It...
🟢 Abcellera Biologics is trading 4.15% up today amid broader Nasdaq strength
Abcellera Biologics is trading 4.15% up at $11.05, broadly aligned with the Nasdaq Composite’s 0.69% gain rather than a newly announced company-specific...
🟢 Abcellera Biologics is trading 4.62% up in pre-market amid Nasdaq Composite’s 0.97% gain
Abcellera Biologics is trading 4.62% up now at $11.10 in pre-market, aligned with stronger futures, particularly the Nasdaq Composite’s 0.97% gain, rather than...
AbCellera's $200 Million Stock Sale Fuels Its Drug Pipeline — But Can the Science Outrun the Dilution?
Shares of AbCellera Biologics slid 7% to $10.53 on August 24 as investors continued digesting a large stock offering that flooded the market with new shares at...
🔴 Abcellera Biologics is trading 7% down today after $200 million offering raises dilution concerns
Abcellera Biologics is trading 7% down at $10.53 as investors continue reacting to its $200 million public offering and dilution concerns. - The offering was...
🔴 Abcellera Biologics falls 4.1% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Abcellera Biologics rises 5.5% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Abcellera Biologics is trading 4.75% down today with no new company-specific catalyst identified
Abcellera Biologics is trading 4.75% down at $10.84 after no new company-specific announcement or analyst action was identified for August 17, 2026. - The...
🟢 Abcellera Biologics is trading 4.34% up today after positive ABCL635 Phase 2 results
Abcellera Biologics is trading 4.34% up at $11.45 after investors continued rewarding positive Phase 2 results for ABCL635, its menopause-related hot-flash...
AbCellera Announces Pricing of $200 Million Public Offering to Fund Pipeline
AbCellera Biologics announced the pricing of an underwritten public offering expected to generate gross proceeds of approximately $200 million. The company...
🟢 Abcellera Biologics is trading 4.15% up today after pricing an oversubscribed $200 million public offering
Abcellera Biologics is trading 4.15% up now at $10.79 after pricing an oversubscribed public offering expected to generate approximately $200 million in gross...
🟢 Abcellera Biologics is trading 4.15% up today after positive ABCL635 Phase 2 results
Abcellera Biologics is trading 4.15% up now at $10.16, extending a sharp multi-session rally after positive Phase 2 results for ABCL635, its investigational...
🔴 Abcellera Biologics is trading 4.2% down today after announcing proposed $200 million share offering
Abcellera Biologics is trading 4.2% down now at $9.35 after announcing a proposed $200 million underwritten offering of common shares and pre-funded...
AbCellera's $200 Million Stock Sale Tests Whether a Hot-Flash Drug Rally Can Survive the Cold Shower of Dilution
Shares of AbCellera Biologics sank 8.6% to $8.92 on August 12 after the Vancouver-based biotech announced a $200 million stock offering — timed just one day...
🔴 Abcellera Biologics is trading 8.61% down in pre-market after announcing a proposed $200 million public offering
Abcellera Biologics is trading 8.61% down at $8.92 in pre-market after announcing a proposed $200 million underwritten public offering. - The financing...
🔴 Abcellera Biologics is trading 5% down today in after-hours trading after sharp regular-session rally
Abcellera Biologics is trading 4.91% down now at $9.28 after a sharp regular-session rally. - Positive ABCL635 Phase 2 results met both primary efficacy...
🟢 Abcellera Biologics is trading 5.9% up today after ABCL635 study meets both primary endpoints
Abcellera Biologics is trading 5.9% up now at $9.89 after positive Phase 2 results for ABCL635, its investigational menopause treatment. - The study met both...
🟢 Abcellera Biologics is trading 31% up today on positive ABCL635 Phase 2 data
Abcellera Biologics is trading 30.88% up now at $9.07 after announcing positive top-line Phase 2 data for ABCL635, a treatment for moderate-to-severe...